Gemtuzumab added to chemotherapy for certain adult AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 60 years old
- You have never had AML treatment before (except up to 7 days of hydroxyurea, or any radiotherapy)
- Your AML is newly diagnosed and fits “de novo” AML, not acute promyelocytic leukemia
- Your AML is favorable-intermediate risk, but you must NOT have FLT3-ITD or FLT3-TKD changes
- Your heart function is good: ejection fraction is 50% or higher
- You must have enough kidney and liver function, and no uncontrolled infection or serious nerve/psychiatric illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether fractionated gemtuzumab can eliminate tiny, hard-to-see leukemia cells left after standard chemotherapy. It targets adults with acute myeloid leukemia (AML) who have measurable residual disease (MRD) rather than active leukemia in the blood.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.